Igene Biotechnology Valuation

Based on Macroaxis valuation methodology, the firm cannot be evaluated at this time. Igene Biotechnology regular Real Value cannot be determined due to lack of data. The prevalent price of Igene Biotechnology is $0.0. Our model calculates the value of Igene Biotechnology from evaluating the firm fundamentals such as Shares Owned By Institutions of 0.47 %, return on asset of -0.0821, and Operating Margin of (124.22) % as well as inspecting its technical indicators and probability of bankruptcy.
Undervalued
Today
0.00
Please note that Igene Biotechnology's price fluctuation is out of control at this time. Calculation of the real value of Igene Biotechnology is based on 3 months time horizon. Increasing Igene Biotechnology's time horizon generally increases the accuracy of value calculation and significantly improves the predictive power of the methodology used.
The fair value of the Igene pink sheet is determined by what a typical buyer is willing to pay for full or partial control of Igene Biotechnology. Since Igene Biotechnology is currently traded on the exchange, buyers and sellers on that exchange determine the market value of Igene Pink Sheet. However, Igene Biotechnology's intrinsic value may or may not be the same as its current market price, in which case there is an opportunity to profit from the mispricing, assuming the market price will eventually merge with its intrinsic value.
Historical Market  0.0 Real  0.0 Hype  0.0
The real value of Igene Pink Sheet, also known as its intrinsic value, is the underlying worth of Igene Biotechnology Company, which is reflected in its stock price. It is based on Igene Biotechnology's financial performance, growth prospects, management team, or industry conditions. The intrinsic value of Igene Biotechnology's stock can be calculated using various methods such as discounted cash flow analysis, price-to-earnings ratio, or price-to-book ratio. That value may differ from its current market price, which is determined by supply and demand factors such as investor sentiment, market trends, or news.
0.00
Real Value
0.00
Upside
Estimating the potential upside or downside of Igene Biotechnology helps investors to forecast how Igene pink sheet's addition to their portfolios will impact the overall performance. We also use other valuation drivers to help us estimate the true value of Igene Biotechnology more accurately as focusing exclusively on Igene Biotechnology's fundamentals will not take into account other important factors:
Hype
Prediction
LowEstimatedHigh
0.000.000.00
Details

Igene Biotechnology Total Value Analysis

Igene Biotechnology is currently estimated to have valuation of 1.1 M with market capitalization of 10.96 K, debt of 0, and cash on hands of 269.29 K. Please note that valuation may be misleading and is a subject to auditing or accounting errors. We encourage investors to vigilantly validate all of the Igene Biotechnology fundamentals before making equity appraisal based on enterprise value of the company

Igene Biotechnology Investor Information

The company recorded a loss per share of 0.0. Igene Biotechnology had not issued any dividends in recent years. Based on the key measurements obtained from Igene Biotechnology's financial statements, Igene Biotechnology is not in a good financial situation at this time. It has a very high probability of going through financial hardship in April.

Igene Biotechnology Asset Utilization

The asset utilization indicator refers to the revenue earned for every dollar of assets a company currently reports. Igene Biotechnology has an asset utilization ratio of 83.15 percent. This indicates that the Company is making $0.83 for each dollar of assets. An increasing asset utilization means that Igene Biotechnology is more efficient with each dollar of assets it utilizes for everyday operations.

Igene Biotechnology Ownership Allocation

Igene Biotechnology has a total of 1.57 Billion outstanding shares. Roughly 99.53 (percent) of Igene Biotechnology outstanding shares are held by general public with 0.47 pct. by outside corporations. Please note that no matter how many assets the company holds, if the real value of the firm is less than the current market value, you may not be able to make money on it.

Igene Biotechnology Profitability Analysis

The company reported the previous year's revenue of 3.96 M. Net Loss for the year was (140.75 K) with profit before overhead, payroll, taxes, and interest of 1.02 M.
Please note that valuation analysis is one of the essential comprehensive assessments in business. It evaluates Igene Biotechnology's worth, which you can determine by considering its current assets, liabilities and future cash flows. The investors' valuation analysis is an important metric that will give you a perspective on different companies. It helps you know the worth of the potential investment in Igene Biotechnology and how it compares across the competition.

About Igene Biotechnology Valuation

The pink sheet valuation mechanism determines Igene Biotechnology's current worth on a weekly basis. Our valuation model uses a comparative analysis of Igene Biotechnology. We calculate exposure to Igene Biotechnology's market risk, different technical and fundamental indicators, and relevant financial multiples and ratios and then compare them to those of Igene Biotechnology's related companies.
Igene Biotechnology, Inc. focuses on the research, development, production, and commercialization of specialty ingredients for human and animal nutrition. IGENE Biotechnology, Inc. was founded in 1981 and is based in Columbia, Maryland. IGENE BIOTECHNOLOGY operates under Agricultural Inputs classification in the United States and is traded on PNK Exchange. It employs 18 people.

8 Steps to conduct Igene Biotechnology's Valuation Analysis

Company's valuation is the process of determining the worth of any company in monetary terms. It estimates Igene Biotechnology's potential worth based on factors such as financial performance, market conditions, growth prospects, and overall economic environment. The result of company valuation is a single number representing a Company's current market value. This value can be used as a benchmark for various financial transactions such as mergers and acquisitions, initial public offerings (IPOs), or private equity investments. To conduct Igene Biotechnology's valuation analysis, follow these 8 steps:
  • Gather financial information: Obtain Igene Biotechnology's financial statements, including balance sheets, income statements, and cash flow statements.
  • Determine Igene Biotechnology's revenue streams: Identify Igene Biotechnology's primary sources of revenue, including products or services offered, target markets, and pricing strategies.
  • Analyze market data: Research Igene Biotechnology's industry and market trends, including the size of the market, growth rate, and competition.
  • Establish Igene Biotechnology's growth potential: Evaluate Igene Biotechnology's management, business model, and growth potential.
  • Determine Igene Biotechnology's financial performance: Analyze its financial statements to assess its historical performance and future potential.
  • Choose a valuation method: Consider the Company's specific circumstances and choose an appropriate valuation method, such as the discounted cash flow (DCF) or comparable analysis method.
  • Calculate the value: Apply the chosen valuation method to the financial information and market data to calculate Igene Biotechnology's estimated value.
  • Review and adjust: Review the results and make necessary adjustments, considering any relevant factors that may have been missed or overlooked.
Note: This is a general outline, and different approaches and methods may be used depending on the type and size of the company being valued. We also recomment to seek professional assistance to ensure accuracy.

Igene Biotechnology Growth Indicators

Investing in growth stocks can be very risky. If the company such as Igene Biotechnology does not do well, investors take a loss on the stock when it is time to sell. Also, because growth stocks typically do not pay dividends, the only opportunity an investor has to make money on their investment is when they eventually sell their shares.
Retained Earnings-52.9 M

Complementary Tools for Igene Pink Sheet analysis

When running Igene Biotechnology's price analysis, check to measure Igene Biotechnology's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Igene Biotechnology is operating at the current time. Most of Igene Biotechnology's value examination focuses on studying past and present price action to predict the probability of Igene Biotechnology's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Igene Biotechnology's price. Additionally, you may evaluate how the addition of Igene Biotechnology to your portfolios can decrease your overall portfolio volatility.
Instant Ratings
Determine any equity ratings based on digital recommendations. Macroaxis instant equity ratings are based on combination of fundamental analysis and risk-adjusted market performance
Funds Screener
Find actively-traded funds from around the world traded on over 30 global exchanges
Portfolio Holdings
Check your current holdings and cash postion to detemine if your portfolio needs rebalancing
Content Syndication
Quickly integrate customizable finance content to your own investment portal